Drugs / ET190L1 ARTEMIS™ T cells
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03895944 | Dec 2017 → Dec 2019 | B-cell non-Hodgkin lymphoma | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT03379493 | Apr → Dec 2018 | B-cell non-Hodgkin lymphoma | Eureka Therapeutics Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT03415399 | Sep 2017 → Dec 2020 | B-cell non-Hodgkin lymphoma | Eureka Therapeutics Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ET190L1 ARTEMIS T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03379493 ↗ |
| Known as | Anti-CD19-ARTEMIS | “Phase 1, Open-label, Single-arm, Dose-escalation Clinical Study Evaluating the Safety and Efficacy of ET190L1 ARTEMIS™ (Anti-CD19-ARTEMIS™) in Relapsed, Refractory B Cell Lymphoma” NCT03415399 ↗ |
| Modality | Cell therapy | “Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) ARTEMIS™ expression construct” NCT03379493 ↗ |
| Route | Intravenous | “administered by intravenous (IV) infusion” NCT03379493 ↗ |
| Target | CD19 | “anti-CD19 (ET190L1) ARTEMIS™ expression construct” NCT03379493 ↗ |